Claims for Patent: 12,264,164

Summary for Patent: 12,264,164

Title:	Method of treatment of symptoms of menopause
Abstract:	The present invention generally relates to novel pharmaceutical formulations containing 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl) hexahydropyrazino [2,1-c] [1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide, methods of preparation thereof and their use in medical therapy.
Inventor(s):	Mike Trower, Monica Lazaro, Derek BUSH, David Elder, Mary Kerr
Assignee:	Kandy Therapeutics Ltd
Application Number:	US18/228,593
Patent Claims:	1. A method of treating vasomotor symptoms, insomnia associated with menopause, sleep disturbances associated with menopause, night time awakenings associated with menopause, or any combination thereof, comprising administering to a human in need thereof a pharmaceutically effective dose of 2-[3,5-Bis(trifluoromethyl)phenyl]-N-{4-(4-fluoro-2-methylphenyl)-6-[(7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl]-3-pyridinyl}-N,2-dimethylpropanamide (Compound A): or a pharmaceutically acceptable salt thereof; wherein compound A or a pharmaceutically acceptable salt thereof is administered in an oral form so as to reach pharmacokinetic (PK) exposures similar to that achieved when a soft gelatin capsule with a filling comprising: (a) Compound A or a pharmaceutically acceptable salt thereof; (b) at least one solubilizer selected from caprylocaproyl polyoxyl-8 glycerides, glycerol monocaprylocaprate, polyoxyl 35 castor oil, and polysorbate 80, or any mixtures thereof; and (c) at least one antioxidant selected from DL-alpha-tocopherol, butylated hydroxytoluene, and butylated hydroxyanisole, or any mixtures thereof is administered. 2. The method of claim 1, the soft gelatin capsule further comprising: (d) at least one emulsifier selected from glyceryl monooleate, and Miglyol 812, or a mixture thereof. 3. The method of claim 1, wherein compound A or a pharmaceutically acceptable salt thereof is administered in an oral form so as to reach pharmacokinetic (PK) exposures similar to that achieved when a soft gelatin capsule with a filling comprising: Compound A; glycerol monocaprylocaprate; Caprylocaproyl polyoxyl-8-glycerides; polysorbate 80; and DL-alpha-tocopherol, is administered. 4. The method of claim 1, wherein compound A or a pharmaceutically acceptable salt thereof is administered in an oral form so as to reach pharmacokinetic (PK) exposures similar to that achieved when a soft gelatin capsule with a filling comprising: Compound A; glycerol monocaprylocaprate; Caprylocaproyl polyoxyl-8-glycerides; polysorbate 80; DL-alpha-tocopherol; and glyceryl monooleate, is administered. 5. The method of claim 1, wherein compound A or a pharmaceutically acceptable salt thereof is administered in an oral form so as to reach pharmacokinetic (PK) exposures similar to that achieved when a soft gelatin capsule with a filling comprising: Compound A present at a concentration from 1% w/w to 10% w/w; Glycerol Monocaprylocaprate present at a concentration ranging from 30% w/w to 40% w/w; Caprylocaproyl polyoxyl-8 glycerides present at a concentration ranging from 7% w/w to 13% w/w; Polysorbate 80 (Tween 80) present at a concentration from 7% w/w to 13% w/w; Glyceryl Monooleate (Peceol) present at a concentration ranging from about 33% w/w to 43% w/w; and DL-alpha tocopherol present at a concentration ranging from 0.05% w/w to 1.5% w/w, is administered. 6. The method of claim 1, wherein compound A or a pharmaceutically acceptable salt thereof is administered in an oral form so as to reach pharmacokinetic (PK) exposures similar to that achieved when a soft gelatin capsule with a filling comprising: Compound A present at a concentration of about 5.00% w/w; Glycerol Monocaprylocaprate present at a concentration of about 37.05% w/w; Caprylocaproyl polyoxyl-8 glycerides present at a concentration of about 9.50% w/w; Polysorbate 80 (Tween 80) present at a concentration of about 9.50% w/w; Glyceryl Monooleate (Peceol) present at a concentration of about 38.00% w/w; and DL-alpha tocopherol present at a concentration of about 0.95% w/w, is administered. 7. The method of claim 1, wherein Compound A or a pharmaceutically acceptable salt thereof is administered in an oral formulation so as to reach the steady-state pharmacokinetic (PK) exposures on Day 7 after once-daily dosing of 120 mg to 160 mg of Compound A of a Cmax from about 840 ng/ml to about 5780 ng/ml, and an AUC within 24 hours (AUC (0-24 h)) after dosing on Day 7 from about 4730 ng*hr/mL to about 29000 ng*hr/mL, wherein said steady-state PK exposures are reached by oral administration after overnight fast. 8. The method of claim 1, wherein Compound A or a pharmaceutically acceptable salt thereof is administered in an oral formulation so as to reach PK exposures on Day 1 after a single oral dose of 120 mg to 160 mg of Compound A of a geometric mean for Cmax from about 2541 ng/ml to about 3090 ng/ml, and a geometric mean of AUC within 24 hours (AUC (0-24 h)) post dose from about 7390 ng*hr/mL to about 10400 ng*hr/mL, wherein said PK exposures are reached by oral administration after overnight fast. 9. The method of claim 1, wherein Compound A or a pharmaceutically acceptable salt thereof is administered in an oral formulation so as to reach steady-state pharmacokinetic (PK) exposures on Day 7 after once-daily dosing of 12-to 160 mg of Compound A of a geometric mean for Cmax from about 2053 ng/ml to about 2991 ng/mL, and a geometric mean of AUC within 24 hours (AUC (0-24 h)) after dosing on Day 7 from about 9080 ng*hr/mL to about 14100 ng*hr/mL, wherein said PK exposures are reached by oral administration after overnight fast. 10. The method of claim 1, wherein Compound A or a pharmaceutically acceptable salt thereof is administered in an oral formulation so as to reach: the steady-state pharmacokinetic (PK) exposures on Day 7 after once-daily dosing of 120 mg to 160 mg of Compound A of a Cmax from about 840 ng/ml to about 5780 ng/mL, and an AUC within 24 hours (AUC (0-24 h)) after dosing on Day 7 from about 4730 ng*hr/mL to about 29000 ng*hr/mL; and PK exposures on Day 1 after a single oral administration of 120 mg to 160 mg of Compound A of a geometric mean for Cmax from about 2541 ng/ml to about 3090 ng/ml, and a geometric mean of AUC within 24 hours (AUC (0-24 h)) post dose from about 7390 ng*hr/mL to about 10400 ng*hr/mL; and steady-state pharmacokinetic (PK) exposures on Day 7 after daily dosing of 120mg to 160 mg of Compound A of a geometric mean for Cmax from about 2053 ng/ml to about 2991 ng/mL, and a geometric mean AUC within 24 hours (AUC (0-24 h)) after dosing on Day 7 from about 9080 ng*hr/mL to about 14100 ng*hr/mL, wherein the foregoing PK exposures are reached by oral administration after overnight fast. 11. The method of claim 1, wherein Compound A or a pharmaceutically acceptable salt thereof is administered at a daily dose of 100 to 160 mg. 12. The method of claim 1, wherein Compound A or a pharmaceutically acceptable salt thereof is administered at a daily dose of 120 mg. 13. The method of claim 2, wherein Compound A or a pharmaceutically acceptable salt thereof is administered at a daily dose of 100 to 160 mg. 14. The method of claim 2, wherein Compound A or a pharmaceutically acceptable salt thereof is administered at a daily dose of 120 mg. 15. The method of claim 3, wherein Compound A or a pharmaceutically acceptable salt thereof is administered at a daily dose of 100 to 160mg. 16. The method of claim 3, wherein Compound A or a pharmaceutically acceptable salt thereof is administered at a daily dose of 120 mg. 17. The method of claim 4, wherein Compound A or a pharmaceutically acceptable salt thereof is administered at a daily dose of 100 to 160 mg. 18. The method of claim 4, wherein Compound A or a pharmaceutically acceptable salt thereof is administered at a daily dose of 120 mg. 19. The method of claim 5, wherein Compound A or a pharmaceutically acceptable salt thereof is administered at a daily dose of 100 to 160 mg. 20. The method of claim 5, wherein Compound A or a pharmaceutically acceptable salt thereof is administered at a daily dose of 120 mg. 21. The method of claim 6, wherein Compound A or a pharmaceutically acceptable salt thereof is administered at a daily dose of 100 to 160 mg. 22. The method of claim 6, wherein Compound A or a pharmaceutically acceptable salt thereof is administered at a daily dose of 120 mg. 23. The method of claim 22, wherein compound A or a pharmaceutically acceptable salt thereof is administered in an oral form so as to reach pharmacokinetic (PK) exposures similar to that achieved when two of said soft gelatin capsules are administered, each of the soft gelatin capsules comprising 60 mg of Compound A.